Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Solar Foods, Webcast, Q2'26

By Inderes8/11/2026, 9:00 AM
Solar Foods

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Maria
00:02 - 00:43

Hello, everyone, and welcome to the Solar Foods Oyj H1 2026 webcast. My name is Maria and I am here today with our CEO, Rami Jokela, and CFO, Ilkka Saura. Rami will kick things off by going through the significant events of the first half of the year. And after that, Ilkka will go through the financial highlights. At the end of the webcast, we have a Q&A and you in the audience have the possibility to ask questions through the chat function. But without further ado, Rami, the stage is yours.

Rami Jokela
00:44 - 26:26

Thank you, Maria. And welcome also from my side. So what is happening at Solar Foods Oyj in the first half of the year? We are implementing our strategy. We are proceeding in our commercialization and industrialization journey, and I would like to highlight some of the key developments. We have our first consumer product launch now in the U.S. market. It is the largest health and performance market globally. And that happened in May. We are very excited about that. Later, I will provide more details regarding that. We have also been very successful in implementing our financing. During the first half of the year, we have secured commitments of more than 100 million, ensuring the funding for our operations and our Factory 02 plan, as we communicated in October last year, that we are using strategic partners for our Factory 02. So I am very happy to announce here as well in the report that we have GEA, which is the global leading food technology company. GEA, as well as Fortum, is a leading provider for renewable energy and decarbonisation in the Nordics. Both companies are our strategic partners as well, developing Factory 02. We have also made a lot of progress in Solein ingredient and application development. We have developed more than 18 new product concepts in the Health & Performance segment, which is key for our customers based on their needs and requirements, and together with customers and our R&D team, we have developed a UHT-stable product. I will tell you more about that very soon. So you can see that all elements—commercial funding, and all our efforts regarding the partnership and development plans—are aligned. The designs are ready for the final investment decision as well as the product application. We are seeing very good development, all in all, in all sectors. So, before we go into all the details. So I would like to reiterate our big picture. So we are in the middle of three major megatrends. We are in a unique position, having a globally leading technology platform to connect all these three megatrends. And what are those? Protein is, of course, the trend and the growth driver for health and wellness, but also GLP-1. Barclays analysts estimated that the global protein market has already reached €1.6 trillion. So, it is a huge market. And growth for the next five years is expected to be 37%. So absolutely enormous growth. So earlier we talked about health and wellness as a megatrend, but you can see that protein has become the centerpiece of this megatrend. Now, the other big mega trend is food sovereignty and the security of supply. Reading the news. What has happened this summer? For example, in terms of climate, extreme heat, forest fires, water scarcity, and drought, you can all understand the impact of El Niño. And if you follow what the European Central Bank is estimating regarding the impact of price increases on commodities. Food commodities are up to 9%. Absolutely. A big impact is actually expected. And then every country is, of course, looking at how to ensure food availability within its borders as well. This reduces dependence on the climate as well. Other countries also rely on fertilizers. Fertilizer volatility has also been unprecedented. If you take a look at the last ten years, fertilizer prices have actually doubled. It's a huge impact as well. That is why many countries have set their national agendas to secure the supply and food sovereignty. So China has their five-year plan. Japan just announced a few weeks back a new $6.2 billion investment for the new food roadmap for 2040. Europe has this Biotech Act number one. And now they are working on Biotech Act number two, focusing on how to secure the food supply in Europe. Number two, how to secure the food supply in Europe. So you can see that a lot of things are happening. It is a strategic topic as such. The last big megatrend I have here is hydrogen, the decarbonization energy transition, and electrification. And if you take a look at what the BloombergNEF analysis put together, there is a 2.1 trillion euro investment annually and 8% growth year on year. At Solar Foods Oyj, we use hydrogen to create our end product, protein. And actually, we are helping a lot from a food sovereignty point of view. If you take hydrogen, the most value-added end product you can create from hydrogen is actually food. And of course, at the same time, we are providing a very good recipe for governments on how to decarbonise as well. You can see we are the centerpiece of that. All right, so let's go to the details. What are the significant events for the first half of the year? All right. I have already commented on that. We have now entered the US Health & Performance nutrition market with our customer, Ambrosia Collective, who launched the Planta RTM brand there. Based on the feedback from the consumers. What we have heard from the Ambrosia Collective. They are very excited and provided very good feedback. It is a best-seller in the company, and you can imagine achieving that kind of position in just two months. And they are already planning more flavors. We understand that Solein actually helps evolve the Planta brand, which is a major topic and confirmation to us that we have something unique as an ingredient for our customers. They are also looking for marketing events to promote the brand, including social media outreach and nationwide distribution through retail chains once those become available. Of course. More to report. Why the U.S. market is so important for us. So we have the health and wellness market. What we have to talk about. But now the GLP-1 topic has arisen and protein demand has been increasing. There is more demand than what was expected. And protein products have actually moved from typically sports users to mainstream users. The US market, which is 10 billion as such, is only for health and performance. Of course, it is a key market for us, and we are very excited. And if you think about what a significant milestone this is for Solar Foods Oyj and the entire new food industry, there are only a few companies that have reached the U.S. market in this space. But if you think about it, we are the first international new food ingredient company entering the US market that is based outside of the US, having publicly available consumer products to buy in the health and performance segment. That is us. So it is a major, major milestone for us. We actually have a first brand available, and consumers can enjoy Solein-blended products. Very good. We are very happy. And thank you for the collective leadership, all the full support, and good cooperation here. We have done a lot of work validating, confirming, and progressing our value proposition. We have four value propositions for Solein. We have sustainability and decarbonisation. We have been marketing and stating that we have the most sustainable protein available. And recently we made a new updated external LCA study, the Life Cycle Assessment study for CO2, and that also confirmed, yes, we are the most sustainable protein available. Supply and price is one. The other one is nutrition. And of course, these cover all the applications. I will provide more details on those now. So if you take a look at the whole protein market and supply and price development, whey protein is the benchmark, specifically whey protein isolate and concentrate. And as we have earlier reported, there is a huge demand for protein, and whey protein, as it is a byproduct of cheese production, cannot cope with the demand. And that is why there is a supply gap. And that supply gap has actually affected two big topics. One is a supply challenge and quality challenges, because now with the type of whey you might actually use, you might have to make compromises for your customers and what they do as well. The price has tripled in the last two years. So you can see that this is actually a major opportunity to have an alternative, high-quality protein like Solein. That is why we stated that Solein enables growth with a stable and discounted price compared to whey. And we have scalable supply and steady quality. So these are the discussions we have with customers, and of course, especially with these big CPG companies and the health and performance companies, this is a big agenda topic for them. So how can they ensure their growth? So we are, of course, ensuring the growth for those companies by providing this very high-quality protein. And then if you take a look in more detail at the price. And here we are using the Vesper price development. And if you take a look at an almost three-year band, you can see that it has tripled the price in WPI, but also whey protein concentrate. And that is the case in both the US and Europe. And you can see that our €17 per kilo, what we have publicly said as a Solein price point, is a very good price for our customers to go for. So that is why you can see that we are confirming our value proposition, the price and supply. If we move to the nutrition, and we have been communicating this many times earlier, we have this 80% protein. And this is a very balanced amino acid profile. All nine essential amino acids, 20% branched-chain amino acids, and 43% essential amino acids. So, it is very comparable. If you look towards this kind of whey concentrate, the way I do it. We also have fibers, with 10% fibers, of which 40% are beta-glucans. And this could be the next big thing. We are already seeing certain trends. Protein is, of course, booming and is a mega trend. But fiber could be the next big thing. The good thing is that Solein has both. And we see that this is very good for us. And then if you think about what customers typically are looking for, they are looking for, is it lactose-free? Is it soy-free? Gluten-free? What is the protein content? How much fiber? Are there any other minerals? How does it taste? And for some customers, this non-GMO status is absolutely key as well. So, we see that we have a very good product available. That is one of the key value propositions we have, and it, of course, gives an alternative to our customers. When I communicated the supply and price challenges happening at the moment in the application area, we did a lot of work, and this has been because of following our customer needs and requirements. We want our Solein ingredient and application to perform the best in our customers' products. I would like to highlight a few areas. So we have these protein bars, protein drinks, and RTM. So for protein bars, for example, we know based on feedback that our value proposition regarding the already validated mouthfeel has been very good. No graininess. This is very smooth as such. And now we have developed one more flavor for that one. Now we have a total of three flavors. RTD, where I already spoke about this treatment, allows us to have a stable product with broad pH and temperature ranges. And this is an absolutely key value for our customers. It remains stable when stored at room temperature or even when chilled. It remains stable at all times and offers very high solubility as well. And we have nine new flavors, and now totally 12. You can see how much effort we have put into developing the RTM area, such as with the Ambrosia Collective partnership in this space. So we have already outstanding binding properties, excellent texture contribution, and also new flavors. Then, we have already ten total flavors, eight developed in the last six months. We also have been doing ongoing development for the ingredient performance and product optimization. So we have improved the Solein powder solubility and handling. And when you have industrial plants, of course, you would like to make sure that there is no dust or anything that goes through smoothly in the process. And of course, the faster dissolution relates to how quickly our Solein will work. Also, 25% reduction in the iron content has been a focus. Our focus. We have been focusing. And we continue, of course, those developments as well. So a lot of work has been done. And all of this work is directed towards our customers. So we follow our customer needs. We want our customers to be successful. We leverage our knowledge as well as what we know about Solein. And that is why we utilize this concept sales model for the different prototypes as well. If we talk about commercial progress. So we have this concept sales model. What was presented at the Capital Markets Day about two years ago. And this is absolutely the work, and this is why it is working so well. So we are able to showcase Solein's capabilities in these kinds of products, like RTD, ready-to-mix, or protein bars. What I explained to you, but also we are collecting and learning how the different flavors, different ingredients, or different treatments actually work. When our customers develop their own value proposition. What they like about the positioning, they have certain ingredient lists, how they are going to use it, and so on. So we have this kind of application know-how to support our customers. And that has been a big, big focus. And we continue investing in this, because this will be the key to making our customers successful very quickly. This is very time-consuming when our customers are doing the application development. So this is absolutely key, perhaps one of the key messages if you would like to take away from today's webcast as well; we have been focusing on agile Health & Performance companies and smaller companies, which are fast in bringing products to the market, while also focusing on large Health & Performance companies and CPG companies. And those are the big, big volumes, especially for Factory 02, and we are turning. Now we have communicated from letter of intent and a memorandum of understanding to the firm offtake agreements. I can report very good continuing progress and discussions back and forth. We are discussing which stage the application development is in and what the launch plans or limited launch plans look like to commercialize that as well. So I can say now that progress has been made and there is more to come. We continue to communicate. Once we can announce which brands we actually have agreements with, we will have something more tangible to say. Solein is commercially available in Singapore and the U.S., and we are very proud of our progress regarding Europe as well. We have been continuing our active work and we expect to receive a European EFSA opinion very soon. We have answered all the questions. We expect that sooner rather than later we will receive the scientific opinion for Solein, and of course, we look forward to it. We hope to get this positive feedback, and then we can start to really make plans. Europe, the launch plans with our customers who are absolutely waiting to get this Solein to the market as well. Below, I have shown the five elements of what a typical customer journey looks like. For the first customer, it might take one to one and a half years, while for big companies, it could take two or even three years. So, introduction and product positioning. Okay, how this brand Solein could actually fit into the portfolio of the company. Application development, where the recipe is developed together with the ingredient list that the customers have and how it fits actually. Then they define their consumer needs and positioning. This typically takes a long, long time. That is something we have seen, and we are supporting our customers a lot. We are investing even more in that area, because we can see that this is where we can accelerate commercialization. And the launch plans are key. So, which channels are our customers using? Then finally. And what is the consumer story? Developing a compelling storyline for that. And of course, we are supporting our customers in that. So how do Solein and the Solar Foods Oyj story fit into the launch plans? And that typically leads now to agreements, like Project Collectiv, which was a good example. But this is a lengthy process, and I can comment if you have any questions about surprises here, that this is perhaps one of the learnings: that this application development takes time. All right, I will continue here. Our concept sales model, which we selected, works. We have now clear evidence with the Project Collective. Also, other customers would. We are in the process of launching in the US at the moment and preparing also in the European Union. And this is now showing actually Factory 01 volumes, and Factory 02 is how we are planning. We want to partner with fast-moving health and performance companies. Small and mid-sized companies get the products to market quickly, but at the same time, you can see that we have leading Health & Performance companies. Those are companies with perhaps more than 1 billion in revenues. And then major CPG, which are multi-billion dollar companies, we are already securing a certain volume from our Factory 01, which is our R&D demo plant, allowing us to perform this testing and facilitate potential limited launches as well. That is our tactical approach to how we operate. And of course, when we move to Factory 02 volumes, clearly the majority of the volumes will come from the big companies. And once again, this concept sales model that we introduced has worked very well. So demonstrating this, we have our own concepts and learnings with the Solein ingredient. How it works and applications to support our customers. It is absolutely key as such. Then, if we talk about our Factory 02, in terms of factory design, we have advanced to the final phase of the design together with our partners. And now we are. We are all the time refining interfaces, timelines, and delivery scopes as well. Actually, that is how this factory will be visualized, but also concretely built in the plans as well. So we are now in the final phase towards this final investment decision with GEA, which is our processing partner. We are, of course, doing the design and engineering together, but also negotiating the supply agreement and a strategic partnership agreement for the network of factories, where the energy services area of Fortum covers cooling, heating, electrics, and hydrogen. These are the four key areas. So we are proceeding with engineering at the moment. And of course, we are having discussions on how we can procure services from Fortum for Factory 02 and establish agreements for that real estate area. We are exploring real estate investor options, and Vicus Capital Advisors has been our partner in finding real estate investor options for that project. All in all, I have to say I am very happy. We have very strong partners. We have even more key partners announced than those listed here. So we are ready actually for Factory 02 indeed and what you already heard. We will hear more about the financing, which looks very good. So now it is more about continuing with the commercial side to make these Factory 02 plans a reality. All right. I will conclude here. So what we actually have, what we are doing here with Factory 02, and why we actually have companies like Fortum, GEA, and other big companies interested to collaborate and be part of that. So what is in the middle? Solar Foods Oyj and Solein. Regarding this technology platform, we have the world's leading gas fermentation technology platform to produce food for humans. And actually, we are the only one that has the permissions to sell that in any country globally. This is also a platform. We are able to produce ten times more efficiently than photosynthesis today. It is a paradigm shift. So food is ready in three days. So, what we are doing now is building a new ecosystem for the food and energy industries together. And you can see what we have. On the left-hand side, we have hydrogen and oxygen. We have Fortum as a selected intended partner, and then we have carbon dioxide and renewable energy. We are currently discussing which companies could be involved in the middle of our technology platform. We have Fortum and GEA. Regarding what I explained already, on the right-hand side, we have food companies that we are working with. And then the health and performance sector. We have protein drinks, protein powder, and protein bars. But then you can see that Solein is a very versatile ingredient. We can go to dairy replacement, egg replacement, and other markets as well later. But we have this kind of phased plan. So first the health and performance and then expanding more. All right. That is perhaps all I can say. So we have something unique here, and we are developing very well. But now might be the right time to tell something more about the financial highlights. So, Ilkka, how would you describe our current financial position?

Ilkka Saura
26:26 - 33:40

Thank you, Rami. Thank you Rami. Hi all. I am very pleased to be here today with you to discuss the first half results report, which has been out for a couple of hours. Here are some of the key figures. Our operating loss stood at 6.8 million euros. We ended the period with a very healthy balance sheet. Well, this is mainly because of the executed funding transactions and the cash flow, showing our commitment towards the investment path and commercializing this asset, Solein, through the network of factories and our partners. As you also might have noted, the P&L was presented in a functional format. I will now discuss a couple of key highlights of the P&L. So, research and development expenditure was approximately €6.4 million. Sales and marketing expenses were at €1.3 million, and general and administrative expenses were at €4 million. It has to be noted that the company continues to recognize the capitalized R&D costs through the P&L in the R&D expenditure. And with this in mind, the adjusted R&D expenses remained at about €8.4 million, at more or less the same level as last year. Again, underlining the fact that the company invests heavily in the future. And the upcoming growth, sales and marketing are, of course, growing from the prior year by about €500,000 due to the accelerated go-to-market activities, especially in the US, but also in Europe. As we are moving towards the anticipated novel food approval in Europe. General and admin included certain non-recurring items such as the transaction fees of the executed equity transaction in January, among other items. Cash flows. Net cash flow was approximately €19.1 million positive due to the funding round. Operating cash flow was at €4.5 million and investment cash flow at €400,000, whereas financing remained at a very healthy €24 million. It is good to note that the company received approximately €8 to €9 million of grants over the period. That is also visible in this report and the prior reports. These have been recognized in both operating cash flow and investment cash flow. And with this in mind, the cash flow into operations and investment increased by about €4 million, mainly because of somewhat material investments to Factory 02 and related working capital and the non-recurring equity transaction, as well as the growth in the sales and marketing expenditure. So this is good to keep in mind. And as cash is king, it is important to note that the cash balance at the end of the period stayed at about €27 million. So very good in that sense. Some of the other key figures, revenue, reported revenue of approximately €100,000, growing from last year, comprised of deliveries to customers in the US and some other parts of the world. Good to also note the decline in the order book, which we have been reporting for quite some time. A certain customer, a small Health & Performance fast-moving company, decided to discontinue its operations and start dissolution. And that supply agreement has been eliminated from the order book. So, one of the key highlights in this report is, of course, the execution of our financial program. So, in October last year, we came out with the funding plan regarding our financing needs with strategic partners, totaling about €190 million in capital requirements. In January this year, during the period, the company successfully executed a directed share issuance to certain strategic partners, as well as institutional investors, family offices, and high-net-worth individuals. And in June, just before the period close, we managed to come out with a significant announcement of a funding package with Business Finland, comprising a grant of about €39.6 million and an R&D loan with somewhat interesting terms of about €38.1 million, of which 30% can be paid in advance. It comes with relatively interesting pricing of 1% interest and a grace period of five years from the initiation of the drawdown. So with this funding package and the equity financing, the message is that the milestones that we promised to the investors have been executed in a very rigorous way, which we are really proud of. Of course. And what this actually means is shown here. So we started this year. Also, while we communicated this funding plan, we had roughly 10% or even single-digit figures secured of this funding package. But now as we release this report, we are very glad to tell you that 71% of this package has been secured. So this is a massive milestone for the company itself. And this is, of course, something that we continue to execute in the future. Also, considering the off-balance sheet items through the build, operate, maintain partnerships with our partners such as Fortum and others. Taking care of about €127 million of capital expenditure. So good news on the funding front. This means that whatever comes to the FID. The company remains confident that the necessary funding exists whenever we are doing the FID. We have made great progress. Progress indeed. Then I want to discuss with you the restatement of the P&L. So. So as you saw, the company has been evaluating its reporting of financials and has decided to report the P&L in the functional format and not the by-nature based format. However, those figures are still reported in the notes of the report and available for investors. And this decision was taken because we want to bring more material information to our investors and potential investors about the expenditure of the firm and also the capital allocation as we move on. On the growth strategy, it is good to note that the gross presentation of internally developed capital expenditure has been discontinued. However, the capitalization is recognized in the R&D expenditure and is also disclosed in the notes. So with these words, I would like to hand over back to you, Rami, for a wrap-up.

Rami Jokela
33:41 - 38:06

Yeah. Thank you. So, the way forward: what to expect now. So during this year, we will continue to execute our strategy. We have been doing very well. Many areas, such as the funding area. Commercial area and factory development area. Also the partnership area as well as application development. As I commented earlier, we are investing heavily in that area. Our target is to be ready for the final investment decision for Factory 02. Factory 02 will make this company different. This company, after Factory 02 is running, will be a profitable company and highly profitable. Based on our plans. So, what do we need in order to make it? We. We need to have sufficient binding customer agreements. That is what we are working on at the moment. And good progress. We are making progress with visits to both parties and meetings. High-level meetings are taking place in corporate boardrooms. We are, of course, building the company and the partner network. We are further preparing for Factory 02, while ensuring that the offtake agreements and next customers are secured, especially in Europe. The design, together with partners which are now selected, for Factory 02 ensures that we have a solid design plan, schedules, CapEx plans, delivery plans, and leadership and governance for that project, while implementing our financing plan. What Ilkka was already commenting on is something we are very happy about. We are happy as well. We are focusing on how development has progressed and how to finalize and implement that plan. Research and development of Solein is an area where I have already invested a significant amount of time. We continue to invest in that, because we know this will be the gate that secures more offtakes and faster customer commitments. And then there are two major milestones which are not fully in our hands. In Europe, we are focused on the novel food approval, specifically the EFSA scientific opinion first, followed by the formal approval. And then, of course, in the US, we have our ongoing work. One year ago, we already applied for the No-Questions Letter. For the U.S. Food and Drug Administration, FDA. So those are the seven major elements. Those are the seven major elements that we are working on. We have proceeded very well. And what you have seen. If we summarize, actually. Regarding the commercial part and our entry into the US market, receiving good feedback is a confirmation that the Solein ingredient works and that consumers are willing to buy it. That is a major milestone we are working on with the offtakes and more launches in the U.S. And once we have Europe approval, certainly here in Europe as well, funding is a key element. Of course, our off-takers are really eager to see the factory construction proceeding. It is also being financed. So you can see that we are working with funding, which looks good, but also all the key partners and those companies who are working with us strategically here are well-known global or regional leaders. So you can see how important this whole company and next project is for us. But actually, many other companies as well are pioneering to build a very good future with this new technology. So, thank you, Business Finland. Thank you to GEA. Thank you for the support, Fortum. Thank you also for the collaboration for the launch. And of course, we still have Ajinomoto and Chermoula and many others who are working. We have not mentioned all details now because we focused actually on what are really new developments in the first half year, but everything looks good. We are progressing in this commercialization. We are progressing in industrialization and that will continue. I believe there are a lot of good questions coming to us. I hope you will come over here and take this, so let's go for the Q&A part.

Maria
38:06 - 38:25

Yes. Thank you Rami. We have received plenty of questions. So let's get going. The first question is for you. Rami, has Ambrosia's Planta product success increased the interest in Solein amongst CPG companies? Should we expect this to lead to a pickup in new orders?

Rami Jokela
38:26 - 39:07

Great question. We know that these big CPG companies, health and performance companies, have been asking us to organize also the Ambrosia Planta RTM products for them because they like the taste as well. It works well now because it is available. I know that there was an event in Chicago recently where this was a major topic, as a new food ingredient is now coming to the market and is available to consumers. That was discussed and was a significant topic among the participants at the IFT in Chicago as well. So the answer is yes.

Maria
39:07 - 39:18

Thank you. And another one for you. What are currently the main concerns of customers that are considering making Solein orders in the United States?

Rami Jokela
39:19 - 40:10

Okay. That is a difficult question. So I do not know all the plans for our customers. The smaller the company, the faster they might move in both directions. I know that for bigger companies, such as health and performance companies and CPG companies, it is a very steady development. It's very steady development. We have a very clear plan regarding how it works. So I can only comment that we are progressing very well. I'm happy to report more progress with the company. And what is the achievement that is expected at the end? But that I can comment. So I'm excited. Absolutely. And my excitement and energy are growing. When I see the customers and consumers, they feel there is something unique. Now we are refining the value proposition. We are helping them to grow the business.

Maria
40:11 - 40:18

Thank you. Will you make the investment decision for Factory 02 this year?

Rami Jokela
40:19 - 40:35

Yeah. We keep to our communicated publicity. So based on this information, what we have at the moment and offtake discussions as well. Expectations for the EFSA opinion. So this is the situation where we are today.

Maria
40:35 - 40:46

Now, to continue a little bit on that topic. Ilkka. How is the company's recent funding progressing? The investment decision for Factory 02.

Ilkka Saura
40:46 - 41:38

Yeah. Take a historical view on this and reflect a little bit. Well, we have been on the road raising these funds. The question sometimes has been, is this company ever capable to raise this amount of money to execute the funding plan and the growth strategy? But I think that the Finnish government is absolutely strongly supporting us. Whenever we are ready for the FID, the FID itself is the main condition for us to draw down these funds, grants, and debt from Business Finland. But they remain committed as well as we are, so it is a very important milestone in that sense and raises the confidence level also in the eyes of our strategic partners and customers that this company really can scale. Also from the funding point of view.

Maria
41:40 - 41:50

Thank you Ilkka, another one for you. Please comment on the movement of the share price at the stock exchange. How diversified are the stockholders?

Ilkka Saura
41:51 - 42:11

Well, of course, this is a question that has to be bypassed according to the lawyers and advisors. So we are not commenting on the share price; the market determines the fair value of the company every single minute. That is why we are also listed. And we of course continue to monitor it.

Maria
42:12 - 42:22

Thank you. Then a question for Rami. When will you get the regulatory approval in the EU and the United States?

Rami Jokela
42:23 - 44:20

Okay. Let's talk about the European Union first. Yeah. Personally and on behalf of our leadership. A lot of work has been done. A lot of visits in Brussels, meeting with decision makers and building an understanding of the opportunity for competitiveness for all of Europe by having Solar Foods Oyj type companies and new ingredients. And this is about food sovereignty. That is what I was talking about. So the results are not in our hands. The decision is based on the EFSA scientific opinion and later by the European Union. But I have to say that a lot of my agenda has been dedicated to ensuring active engagement with the European Union. We will receive this scientific opinion, and we have answered all the questions. So now we expect to get an answer and a positive answer from EFSA when they are ready to release it, as we have a self-GRAS status. So, we are able to bring the product to the market already, as you can see. And it was a key milestone. We applied for this no-questions letter one month ago, as this represents the highest level of regulatory evaluation. So it has taken perhaps a bit more time. And that is not in our hands. Regarding the FDA, what kind of resources they have and what their pipeline looks like is up to them. But we expect that process is one we are part of as well. If you look publicly, are we in a queue? Are we not? We expect to be now in the final queue where they start to go through those applications very soon as well.

Maria
44:21 - 44:37

Thank you. Rami, you mentioned progress in turning LOIs into binding offtake agreements. Could you shed some light on the progress happening behind the scenes to help us outsiders understand and appreciate the ongoing work.

Rami Jokela
44:37 - 46:46

I will take a concrete example without disclosing. Of course. The name. Name of the huge company. Regarding application development, you have the five phases I presented: introduction, positioning, and then the application development itself. One of these huge companies, the. They commented, can we help them and give prototypes and concepts as well? So we developed 26 different sub-concepts in three months based on their ingredients and the ingredient list they provided. And then, of course, we need to multiply that, from a stability point of view, another 26 times. So we really dedicated our resources to make this perfect. And then there was a meeting over the summer where we reviewed how our concepts were performing, and the feedback was very good. So really, the feedback was positive. Now we have progressed and helped as well. That company to understand what you can do with Solein and how good Solein is as well. A comment like this was made regarding the protein bars that we are using. So this is the work that we need to do. The company must be engaged at all levels, from the highest boardroom and C-level leaders to the application development and quality departments. All of them need to be happy with our ingredient. And that is the work that we are doing. Confirming that yes, everybody feels that now the application recipe is ready. And now, let's move to our launch plans and how we are executing them. Which markets are we targeting for seasonal or limited launches? So we are progressing it, but I cannot comment before we have a really tangible logo there. Actually, it is a unique set of figures to announce. Once those are available, you can expect that this information will be released. But we have very good discussions. Many of those companies. Indeed, I hope this will help to understand the work we are doing.

Ilkka Saura
46:46 - 47:25

It is also worth noting that these customers and companies are following very closely what is happening on the regulatory front. So, EFSA's opinion is being very rigorously awaited by these customers. One of the highest-level authorities in the world issuing a scientific opinion on the product safety is certainly something that they monitor very closely, because that then affects also acceptances and processes outside the European Union. So that is also important to keep in mind. EFSA is also a very major lever in this sense.

Maria
47:25 - 47:34

Thank you. Let's take one more question, Rami. What are the next steps in the Solein commercialization journey?

Rami Jokela
47:36 - 49:05

We have three very key priorities. We will continue launching more in the US, together with Ambrosia Collective as I commented, but with other brands as well. So we are fast-moving to get consumer feedback, then opening the market in Europe. That is our biggest strategic goal because the home market and all the work that we have done over several years, with many of the customers like Ilkka Saura was commenting on, is nearing fruition. It is becoming tangible. And then a third one is offtakes for the big volumes for Factory 02. So we have been working and investing heavily to make these applications ready, and the products are ready so that they can see that this is the product concept that our big customers could actually launch once we have volume commitments. And then this is leading us towards this final investment decision. An effort to scale. So those three are key to our centerpiece. And. And one more time, for this company, our key focus is commercial mega-success. And this is coming through this application and ingredient performance and this value proposition that I presented. So to make sure that those are really fully understood, but also used to the benefit of our customers and consumers, who will be excited by Solein-based products later.

Maria
49:06 - 49:19

Thank you. Rami. Thank you. Ilka. And thank you, everybody in the audience. This concludes our webcast. Thank you very much for joining, and see you next time. Again, have a great rest of the day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…